申请人:Shionogi Co., Ltd.
公开号:EP1787979A1
公开(公告)日:2007-05-23
It is considered that MMP-13 inhibitors contribute to the treatment or prevention against the diseases caused by or related to activity of MMP-13, especially osteoarthritis (OA). Therefore, the development of MMP-13 inhibitors has been desired.
A compound represented by the general formula (I):
wherein Z is 1,4-phenylene and the like; R1 is hydroxy and the like; R2 is hydrogen atom, optionally substituted lower alkyl, and the like; R12 is hydrogen atom; or R2 and R12 taken together with the adjacent carbon atom may form a ring; R3 is hydrogen atom, optionally substituted lower alkyl, and the like; R4 is halogen, lower alkyl, and the like; m is 0, 1, or 2; X is a bond, -C≡C-, and the like; Y is optionally substituted phenyl, optionally substituted naphthyl, and the like, its optically active substance, their pharmaceutically acceptable salt, or a solvate thereof.
人们认为,MMP-13 抑制剂有助于治疗或预防由 MMP-13 活性引起或与之相关的疾病,尤其是骨关节炎(OA)。因此,人们希望开发 MMP-13 抑制剂。
通式(I)代表的化合物:
其中 Z 是 1,4-亚苯基等;R1 是羟基等;R2 是氢原子、任选取代的低级烷基等;R12 是氢原子;或 R2 和 R12 与相邻碳原子一起可形成一个环;R3 是氢原子、任选取代的低级烷基等;R4 是卤素、低级烷基等;m 是 0、1 或 2;X 是键、-C≡C- 等;Y 是任选取代的苯基、任选取代的萘基等,其光学活性物质、它们的药学上可接受的盐或其溶液。